US-based Inotek Pharmaceuticals has appointed Martin Carroll to its board of directors and elected him as chairman of the board.
He will succeed current chairman Argeris Karabelas upon his resignation from the board, which takes effect on 23 June.
Caroll brings over 35 years of experience in the pharmaceutical industry to the board, including 25 years at Merck & Co. where he held increasingly senior roles, finally as executive vice president, customer marketing and sales.
After leaving Merck & Co in 2001, Carroll served as president and chief executive officer of Boehringer Ingelheim in the US, before becoming its head of global strategy.
He currently serves as a member of the board of directors at Catalent, Mallinckrodt Pharmaceuticals and TherapeuticsMD.
David Southwell, president and chief executive officer of Inotek, said: “Mr Carroll has a track record of success as a pharmaceutical industry leader and will bring operational experience in many areas including R&D, manufacturing and sales.
“His diverse expertise will be invaluable to us as we further develop Inotek into a leading ophthalmology company.”
Carroll said: “The Company’s world class leadership team and board of directors demonstrates their commitment to bring novel ocular therapies to market for patients.
“I look forward to working closely with Inotek’s management and board.”